Hormone level may reflect mortality risk among dialysis patients
Wednesday, August 6, 2008 - 16:28
in Health & Medicine
A new study suggests that monitoring levels of a hormone called fibroblast growth factor 23 (FGF-23) may provide information crucial to the treatment of patients with kidney failure. In the Aug. 7 New England Journal of Medicine, researchers from Massachusetts General Hospital (MGH) report that patients with elevated levels of FGF-23 when beginning hemodialysis had a significantly increased risk of death within the first year of treatment, regardless of whether they had other risk factors. The study also found evidence that FGF-23 levels may differ between racial groups, which may relate to observed disparities in survival of dialysis patients.
Read the whole article on Physorg
More from Physorg
Related
- Hormone level may reflect mortality risk among dialysis patientsWed, 6 Aug 2008, 17:29:02 EDT
- Study finds optimal type of dialysis treatment differs among kidney disease patientsThu, 18 Dec 2008, 7:18:35 EST
- Controlling bone disease improves survival of hemodialysis patientsWed, 2 Jul 2008, 13:08:09 EDT
- Drug lowers body's 'set point' to control hyperparathyroidism in dialysis patientsThu, 17 Jul 2008, 6:28:44 EDT
- Growth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapySun, 3 Aug 2008, 11:35:43 EDT